CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of
1995) about the benefits of the license and collaboration with AC Immune, and reflects Lilly's current beliefs. However, as with
any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization.
Among other things, there can be no guarantee that Lilly will realize the expected benefits of the license and collaboration,
or that the license and collaboration will yield a commercially successful product. For a further discussion of these and other
risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms
10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
information, please contact:
Corporate – Europe
79 281 6494
AC Immune Media Relations
Phone: +1 617-792-3937
970 987 26 54
Lilly Media Relations
Phone: +1 317 276 5795
Lilly Investor Relations
Phone: +1 317 277 1838
AC Immune SA